flash-finance

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced it has acquired Orphai Therapeutics Inc., a clinical-stage biotechnology company. The acquisition brings Orphai’s lead program LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor

Quince announces acquisition of Orphai and up to $187M private placement to advance pulmonary pipeline

Legal action stemmed from leak of tax documents

Analysis earlier this year concluded that decommissioning the scheme could cost as much as continuing to build the railway

A new era of elevated borrowing costs is potentially underway as war-driven inflation angst intensifies in the US bond market, sending 30-year yields toward a two-decade high above 5%. Guneet Dhingra, Head of US Rates Strategy at BNP Paribas, discusses the recent yield surge and why 5% may become th

Sitara Sundar, Head of Alternative Investment Strategy at JPMorgan Private Bank, says strong earnings are offsetting inflation concerns and AI demand is still outstripping supply. She speaks to Bloomberg's Matt Miller on 'Open Interest.' (Source: Bloomberg)

Ford unit signs five-year energy storage deal with EDF

Lam Research gets an upgrade, Applied Materials cut at Morgan Stanley

Ford inks 5-year energy storage deal with EDF, shares up

Berkshire Hathaway took a $2.6 billion stake in Delta Airlines and increased its shares in Alphabet by 224%.